Novartis eye drug works at less frequent dosing than rival's

Novartis eye drug works at less frequent dosing than rival's


FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. Novartis eye drug RTH258 works as well as a rival product from Regeneron and at less frequent dosing in clinical trials, the Swiss drugmaker said on Tuesday, boosting its shares.



from Biotech News